NBIX Valuation

Neurocrine Biosciences Inc

Add to Watchlist

Advanced Chart

141.960

-1.25(-0.873%)1D

NBIX Relative Valuation

NBIX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NBIX is overvalued; if below, it's undervalued.

Historical Valuation

Neurocrine Biosciences Inc (NBIX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 16.03 is considered Undervalued compared with the five-year average of 22.25. The fair price of Neurocrine Biosciences Inc (NBIX) is between 153.52 to 231.55 according to relative valuation methord. Compared to the current price of 141.96 USD , Neurocrine Biosciences Inc is Undervalued By 7.53%.

Relative Value

Fair Zone

153.52-231.55

Current Price：141.96

7.53%

Undervalued

16.03

Trailing

Forward

19.91

EV/EBITDA

Neurocrine Biosciences Inc. (NBIX) has a current EV/EBITDA of 19.91. The 5-year average EV/EBITDA is 22.64. The thresholds are as follows: Strongly Undervalued below 7.96, Undervalued between 7.96 and 15.30, Fairly Valued between 29.98 and 15.30, Overvalued between 29.98 and 37.32, and Strongly Overvalued above 37.32. The current Forward EV/EBITDA of 19.91 falls within the Historic Trend Line -Fairly Valued range.

16.42

EV/EBIT

Neurocrine Biosciences Inc. (NBIX) has a current EV/EBIT of 16.42. The 5-year average EV/EBIT is 24.13. The thresholds are as follows: Strongly Undervalued below 9.63, Undervalued between 9.63 and 16.88, Fairly Valued between 31.38 and 16.88, Overvalued between 31.38 and 38.63, and Strongly Overvalued above 38.63. The current Forward EV/EBIT of 16.42 falls within the Undervalued range.

143.21

Neurocrine Biosciences Inc. (NBIX) has a current PS of 143.21. The 5-year average PS is 6.20. The thresholds are as follows: Strongly Undervalued below -7.52, Undervalued between -7.52 and -0.66, Fairly Valued between 13.06 and -0.66, Overvalued between 13.06 and 19.92, and Strongly Overvalued above 19.92. The current Forward PS of 143.21 falls within the Strongly Overvalued range.

16.66

P/OCF

Neurocrine Biosciences Inc. (NBIX) has a current P/OCF of 16.66. The 5-year average P/OCF is 21.96. The thresholds are as follows: Strongly Undervalued below 14.33, Undervalued between 14.33 and 18.15, Fairly Valued between 25.78 and 18.15, Overvalued between 25.78 and 29.59, and Strongly Overvalued above 29.59. The current Forward P/OCF of 16.66 falls within the Undervalued range.

15.64

P/FCF

Neurocrine Biosciences Inc. (NBIX) has a current P/FCF of 15.64. The 5-year average P/FCF is 24.31. The thresholds are as follows: Strongly Undervalued below 16.74, Undervalued between 16.74 and 20.52, Fairly Valued between 28.09 and 20.52, Overvalued between 28.09 and 31.87, and Strongly Overvalued above 31.87. The current Forward P/FCF of 15.64 falls within the Strongly Undervalued range.

Neurocrine Biosciences Inc (NBIX) has a current Price-to-Book (P/B) ratio of 4.75. Compared to its 3-year average P/B ratio of 5.46 , the current P/B ratio is approximately -12.99% higher. Relative to its 5-year average P/B ratio of 6.20, the current P/B ratio is about -23.27% higher. Neurocrine Biosciences Inc (NBIX) has a Forward Free Cash Flow (FCF) yield of approximately 4.15%. Compared to its 3-year average FCF yield of 3.44%, the current FCF yield is approximately 20.67% lower. Relative to its 5-year average FCF yield of 3.03% , the current FCF yield is about 37.01% lower.

4.75

P/B

Median3y

5.46

Median5y

6.20

4.15

FCF Yield

Median3y

3.44

Median5y

3.03

Competitors Valuation Multiple

The average P/S ratio for NBIX's competitors is 54.49, providing a benchmark for relative valuation. Neurocrine Biosciences Inc Corp (NBIX) exhibits a P/S ratio of 143.21, which is 162.80% above the industry average. Given its robust revenue growth of 27.78%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

NBIX.O

Neurocrine Biosciences Inc

Summit Therapeutics Inc

Elanco Animal Health Inc

BioMarin Pharmaceutical Inc

52.85

4.08%

10.15B

Performance Decomposition

Market capitalization of NBIX increased by 12.00% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 622.10M to 794.90M.

The secondary factor is the Margin Expansion, contributed 26.37%to the performance.

Overall, the performance of NBIX in the past 1 year is driven by Revenue Growth. Which is more sustainable.

27.78%

622.10M → 794.90M

Revenue Growth

26.37%

20.86 → 26.36

Margin Expansion

-42.15%

59.06 → 34.17

P/E Change

12.00%